Likewise, we have not addressed possible therapeutic interventions such as the use of thrombopoietin [29] receptor agonists [30,31] originally developed for immune thrombocytopenia [32,33], which may have good efficacy in cytopenic patients with a normal bone marrow evaluation. The gene discussed is THPO; the disease is autoimmune thrombocytopenic purpura.